Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients

Ezra E W Cohen, Kehua Wu, Christine Hartford, Masha Kocherginsky, Kimberly Napoli Eaton, Yuanyuan Zha, Anitha Nallari, Michael L. Maitland, Kammi Fox-Kay, Kristin Moshier, Larry House, Jacqueline Ramirez, Samir D. Undevia, Gini F. Fleming, Thomas F. Gajewski, Mark J. Ratain

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Purpose: Sirolimus is the eponymous inhibitor of the mTOR; however, only its analogs have been approved as cancer therapies. Nevertheless, sirolimus is readily available, has been well studied in organ transplant patients, and shows efficacy in several preclinical cancer models. Experimental Design: Three simultaneously conducted phase I studies in advanced cancer patients used an adaptive escalation design to find the dose of oral, weekly sirolimus alone or in combination with either ketoconazole or grapefruit juice that achieves similar blood concentrations as its intravenously administered and approved prodrug, temsirolimus. In addition, the effect of sirolimus on inhibition of p70S6 kinase phosphorylation in peripheral T cells was determined. Results: Collectively, the three studies enrolled 138 subjects. The most commonly observed toxicities were hyperglycemia, hyperlipidemia, and lymphopenia in 52%, 43%, and41%of subjects, respectively. The target sirolimus area under the concentration curve (AUC) of 3,810 ng-h/mL was achieved at sirolimus doses of 90, 16, and 25 mg in the sirolimus alone, sirolimus plus ketoconazole, and sirolimus plus grapefruit juice studies, respectively. Ketoconazole and grapefruit juice increased sirolimus AUC approximately 500% and 350%, respectively. Inhibition of p70 S6 kinase phosphorylation was observed at all doses of sirolimus and correlated with blood concentrations. One partial response was observed in a patient with epithelioid hemangioendothelioma. Conclusion: Sirolimus can be feasibly administered orally, once weekly with a similar toxicity and pharmacokinetic profile compared with other mTOR inhibitors and warrants further evaluation in studies of its comparative effectiveness relative to recently approved sirolimus analogs.

Original languageEnglish (US)
Pages (from-to)4785-4793
Number of pages9
JournalClinical Cancer Research
Volume18
Issue number17
DOIs
StatePublished - Sep 1 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Cohen, E. E. W., Wu, K., Hartford, C., Kocherginsky, M., Eaton, K. N., Zha, Y., Nallari, A., Maitland, M. L., Fox-Kay, K., Moshier, K., House, L., Ramirez, J., Undevia, S. D., Fleming, G. F., Gajewski, T. F., & Ratain, M. J. (2012). Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clinical Cancer Research, 18(17), 4785-4793. https://doi.org/10.1158/1078-0432.CCR-12-0110